Sugi Predict

Sugi Predict / Compounds / SCHEMBL118809

SCHEMBL118809

SCHEMBL118809

Cc1ccc(C(Cl)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.48
▸ ACHE P22303 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ KIF11 P52732 8/20 0.47
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ XBP1 P17861 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484318 1.00 TSHR (0.48) TSHRACHELMNAALOX12KIF11
Chlorotriphenylmethane SCHEMBL29248291 0.92 TSHR (0.58) TSHRACHELMNAALOX12KIF11
SCHEMBL11527250 0.89 TSHR (0.55) TSHRACHELMNAALOX12HPGD
SCHEMBL11588689 0.89 TSHR (0.55) TSHRACHELMNAALOX12HPGD
SCHEMBL12379580 0.88 KIF11 (0.44) TSHRACHELMNAALOX12KIF11
SCHEMBL13379252 0.88 KIF11 (0.40) TSHRACHELMNAALOX12KIF11
SCHEMBL16321127 0.86 ACHE (0.56) TSHRACHELMNAKIF11SMN1; SMN2
SCHEMBL17753724 0.86 KIF11 (0.47) TSHRLMNAKIF11MEN1KMT2A
SCHEMBL12730666 0.86 ACHE (0.56) TSHRACHELMNAKIF11SMN1; SMN2
SCHEMBL7644095 0.85 TSHR (0.48) TSHRACHELMNAALOX12KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725957-A1 GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2026-04-15 — — EP claimed
CN-114874293-B Cyclic polypeptide compound and preparation method and application thereof 中国医学科学院医药生物技术研究所 2025-05-23 — — CN claimed
WO-2025094036-A1 A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE PIRAMAL PHARMA LIMITED (IN) 2025-05-08 — — WO claimed
CN-119707960-A Preparation method of side chain Fmoc-His (Mtt) 四川鸿日医药科技有限公司 2025-03-28 — — CN claimed
CN-119504882-A Synthesis method of GalNAc derivative 北京炫景瑞医药科技有限公司 2025-02-25 — — CN claimed
WO-2024250929-A1 GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国医学科学院医药生物技术研究所 2024-12-12 — — WO claimed
CN-119101129-A Cyclic alkaline lipopeptide compound and preparation method and application thereof 中国医学科学院医药生物技术研究所 2024-12-10 — — CN claimed
CN-119019354-A Compound and preparation method and application thereof 北京炫景瑞医药科技有限公司 2024-11-26 — — CN claimed
CN-118994172-A Preparation method of poncirtinib phosphate 广州科锐特生物科技有限公司 2024-11-22 — — CN claimed
WO-2023105497-A1 SYNTHESIS OF GLP-1 ANALOGUES ANTHEM BIOSCIENCES PVT. LTD. (IN) 2023-06-15 — — WO claimed
EP-1575990-A4 METHODS, COMPOSITIONS AND LIBRARIES PERTAINING PNA DIMER AND PNA OLIGOMER SYNTHESIS APPLERA CORP (US) 2007-04-18 — — EP claimed
EP-1575990-A2 METHODS, COMPOSITIONS AND LIBRARIES PERTAINING PNA DIMER AND PNA OLIGOMER SYNTHESIS Applera Corporation (US) 2005-09-21 — — EP claimed
US-20050130228-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2005-06-16 — — US claimed
US-20040142355-A1 Methods, compositions and libraries pertaining to PNA dimer and PNA oligomer synthesis BOSTON PROBES, INC. 2004-07-22 — — US claimed
US-20040137469-A1 Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis BOSTON PROBES, INC. 2004-07-15 — — US claimed
WO-2004022578-A2 METHODS, COMPOSITIONS AND LIBRARIES PERTAINING PNA DIMER AND PNA OLIGOMER SYNTHESIS APPLERA CORPORATION (US) 2004-03-18 — — WO claimed
US-20030138847-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2003-07-24 — — US claimed
CN-1427743-A Dosage forms of polymeric carriers, their use in organic chemical synthesis and process for producing said dosage forms LONDBERK AS H (DK) 2003-07-02 — — CN claimed
EP-1268050-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. Lundbeck A/S (DK) 2003-01-02 — — EP claimed
WO-2001068598-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. LUNDBECK A/S (DK) 2001-09-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040137469-A1 Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis NCL, RNGTT, SSB TSHR 3466/4885ACHE 3892/4885LMNA 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.